Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6515626 | 0.89 | PLK1 (0.49) | AURKAKDRAURKBCHEK1PIM1 | |
| SCHEMBL6514411 | 0.89 | PLK1 (0.51) | AURKAKDRAURKBCHEK1PIM1 | |
| SCHEMBL6518373 | 0.88 | AURKA (0.47) | AURKAKDRAURKBCHEK1PIM1 | |
| SCHEMBL6507966 | 0.84 | PIM1 (0.45) | PIM1PIM3CNR2CAMK2DDRD2 | |
| SCHEMBL6519106 | 0.83 | CHEK1 (0.52) | CHEK1PIM1PIM3CNR2CAMK2D | |
| SCHEMBL6523086 | 0.82 | AURKA (0.57) | AURKAKDRAURKBCHEK1ALDH1A1 | |
| SCHEMBL6533402 | 0.81 | CHEK1 (0.44) | AURKAKDRAURKBCHEK1PIM1 | |
| SCHEMBL6508615 | 0.81 | DYRK1A (0.53) | CHEK1CNR2DRD2PLK1BRD4 | |
| SCHEMBL6521419 | 0.80 | PLK1 (0.43) | AURKAKDRAURKBCHEK1PIM1 | |
| SCHEMBL6514156 | 0.80 | AURKA (0.50) | AURKAKDRAURKBCHEK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | AURKA 78/4885KDR 1094/4885AURKB 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.